Blackstone Emerges As Likely Buyer Of Takeda OTC Business
Up To $2.8bn Deal Soon?
Private equity group Blackstone is reportedly near a deal to acquire Takeda's consumer health business in Japan for up to $2.8bn as the Japanese pharma firm continues to shed non-core assets.
You may also be interested in...
Asia Deal Watch: Takeda Will Employ Engitix’s ECM Tech In Liver Fibrosis Indications
Takeda’s collaboration with the private UK biotech includes NASH and other liver disorders. Reliance will take on Amazon in the India pharmacy space with acquisition of Netmeds.
Alnylam Secures $2bn Financing From Blackstone By Monetizing Inclisiran Royalties
Alnylam successfully completed a multi-pronged financing deal with the investment firm, which it will use to fund the development of more RNAi drugs.
Ferring And Blackstone Launch Gene Therapy Company
The Swiss group has decided to launch FerGene with the private equity giant to give the gene therapy nadofaragene firadenovec, which has a priority review at the FDA, a better chance for a successful launch in the US.